Appropriate Use of Dopamine Agonists and Levodopa in                                         Restless Legs Syndrome in an Ambulatory Care                                         Setting

Molokwu, Ogochukwu

doi:10.1345/aph.1k667

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dopamine precursor levodopa was used for years for RLS treatment until the newer dopamine agonists were introduced. Levodopa is effective in improving RLS symptoms, but rebound (worsening of symptoms in the early morning hours) and augmentation (earlier onset of symptoms in the evening or afternoon, increase in symptoms, and spread of symptoms to involve other extremities) can occur in up to 82% of patients (Allen & Earley, 1996;Molokwu, 2008;Stiasny, Robbecke, Schuler, & Oertel, 2000).…”

Section: Science Of the Clinical Care Of Rlsmentioning

confidence: 99%

“…Dopamine agonists are the drugs of choice for treatment of RLS, largely due to their ability to relieve moderate-to-severe RLS symptoms with fewer side effects than the precursors (Baker, White, & Coleman, 2008;Garcia-Borreguero et al, 2007;McCormack & Siddiqui, 2007;Molokwu, 2008;Trenkwalder, 2006). These medications produce dopaminelike effects at the actual receptor sites (subtypes D 1 through D 3 ).…”

Section: Science Of the Clinical Care Of Rlsmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the Science of Genomics in Restless Legs Syndrome

Cuellar

2010

Biological Research For Nursing

View full text Add to dashboard Cite

Restless legs syndrome (RLS) is a sleep and movement disorder that affects up to 15% of the population across the lifespan. Many health care providers have doubted its validity as an illness and are uncertain as to the implications of health care outcomes. The cause of RLS is unknown. Common treatment options include dopaminergics, benzodiazepines, and opioids; however, the pharmacogenetic mechanisms of treatment are unknown. One of the greatest genetic discoveries in 2007 was the identification of genetic variance associated with RLS. There is, however, a lack of knowledge related to RLS and its genetic basis. Therefore, the purposes of this article are to (a) provide information about the science of clinical care related to RLS; (b) present a systematic review of the literature on the status of genetics/genomics of RLS, including the discovery of associated genetic variance; and (c) identify implications of the current state of the science for health care providers and biobehavioral researchers. With the continuing genetic discoveries in RLS, health care providers, specifically nurses who play a major role in research, genetic counseling, and education, need to understand the implications of this sleep and movement disorder for patients across the lifespan.

show abstract

Section: Science Of the Clinical Care Of Rlsmentioning

confidence: 99%

Section: Science Of the Clinical Care Of Rlsmentioning

confidence: 99%

Advances in the Science of Genomics in Restless Legs Syndrome

Cuellar

2010

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

“…Carbidopa/levodopa and dopamine agonists (pramipexole, ropinirole) are 2 commonly used dopaminergic medications in adult populations. Ropinirole was the first Food and Drug Administration (FDA)-approved medication for treatment of moderate to severe primary RLS as of May 2005 37. Subsequently, pramipexole was approved for the same indication in November 2006.…”

Section: Managementmentioning

confidence: 99%

Diagnosis and management of restless legs syndrome in children

Simakajornboon

Kheirandish‐Gozal

Gozal

2009

Sleep Medicine Reviews

View full text Add to dashboard Cite

Summary Recent published evidence suggests that restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) are common condition in children and adolescents. It is likely that if left untreated, RLS and PLMD may lead to adverse cardiovascular and neurocognitive consequences. However, the diagnosis of RLS and PLMD in children is challenging, particularly because children are relatively unable to describe typical RLS symptoms. The International Restless Legs Study Group has recently published consensus criteria for the diagnosis of RLS and PLMD in children. In addition to clinical description of RLS symptoms, supportive evidence including the presence of clinical sleep disturbances, documented periodic limb movements in sleep from overnight sleep study and family history of restless legs syndrome may be required. Few if any controlled studies have addressed the management of RLS and PLMD, which may involve both non-pharmacologic and pharmacologic approaches. In this context, the importance of avoidance of aggravating factors and good sleep hygiene cannot be overemphasized. Children with evidence of low-iron storage, i.e., low-serum ferritin and/ or iron levels may likely benefit from iron therapy. While there is overall limited experience regarding the use of dopaminergic agents in children with RLS and PLMD, published reports suggesting efficacy of compounds such as levodopa, ropinirole, pramipexole and pergolide have emerged. Other medications including benzodiazepine, anti-convulsants, alpha-adrenergic and opioid medications have not been adequately studied in children. Children with RLS and PLMD should have regular follow-up visits to evaluate clinical improvement and to monitor adverse effects from the selected therapy. Based on aforementioned findings, it is clear that a substantial research effort is needed to evaluate the pathophysiology,

show abstract

L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?

Huot

2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Appropriate Use of Dopamine Agonists and Levodopa in Restless Legs Syndrome in an Ambulatory Care Setting

Abstract: The findings of this study confirm the need for provider education about the appropriate use of levodopa and dopamine agonists in patients with RLS. Appropriate use of these drugs may help decrease unnecessary adverse effects, complications, and costs.

Cited by 4 publications

References 30 publications

Advances in the Science of Genomics in Restless Legs Syndrome

Advances in the Science of Genomics in Restless Legs Syndrome

Diagnosis and management of restless legs syndrome in children

L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?

Contact Info

Product

Resources

About